Assessment of new pathological markers in early stage colon cancer: Insights and limitations

doi:10.4251/wjgo.v17.i3.101325

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (155)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

HTML

Tables (1-2)

Sum=125

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=22

Mar 15, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Mar 15, 2025; 17(3): 101325
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.101325

Assessment of new pathological markers in early stage colon cancer: Insights and limitations

Bulent Erdogan, Fatma Elif Usturalı Keskin, Erkan Özcan, Ahmet Küçükarda, Ali Kaan Güren, Osman Köstek, Bekir Muhammet Hacioglu, Hilmi Kodaz

Bulent Erdogan, Department of Medical Oncology, Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22000, Türkiye

Fatma Elif Usturalı Keskin, Department of Pathology, Trakya University School of Medicine, Trakya University, Edirne 22000, Türkiye

Erkan Özcan, Division of Medical Oncology, Trakya University School of Medicine, Edirne 22000, Türkiye

Ahmet Küçükarda, Bekir Muhammet Hacioglu, Division of Medical Oncology, Department of Internal Medicine, Trakya University School of Medicine, Edirne 22000, Türkiye

Ali Kaan Güren, Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Marmara University, Istanbul 34000, Türkiye

Osman Köstek, Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34000, Türkiye

Hilmi Kodaz, Department of Medical Oncology, Acibadem Eskisehir Hospital, Eskisehir 26130, Türkiye

Author contributions: Erdogan B conceptualized the study; Özcan E, Küçükarda A, Güren AK provided study material or patients; Köstek O, Kodaz H curated the data; Kodaz H performed formal analysis; Erdogan B, Hacioglu BM developed the methodology; Usturalı Keskin FE contributed to the pathological analysis; Erdogan B, Kodaz H contributed to revision of the manuscript.

Institutional review board statement: Approved by Trakya University Ethics Committee, No. TUTF-BAE2020/336.

Informed consent statement: Since this is a retrospective study, informed consent was not required from the patients.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Hilmi Kodaz, Professor, Department of Medical Oncology, Acibadem Eskisehir Hospital, Hosnudiye District, Eskibaglar Street, No. 19 Tepebası, Eskisehir 26130, Türkiye. hilmikodaz@hotmail.com

Received: September 10, 2024
Revised: November 9, 2024
Accepted: December 12, 2024
Published online: March 15, 2025
Processing time: 156 Days and 13.9 Hours

Core Tip

Core Tip: When their associations with the pathological marker in the risk group were evaluated, it was found that there was a significant correlation between the presence of poorly differentiated clusters (PDC) and the presence of PDC grade 3 and advanced T stage. This showed us that PDC is one of the markers to be used in cases where these risk factors are insufficient.